Online-Trading Portfolio-Tracker Research Back-Office MF-Tracker
BSE Prices delayed by 5 minutes... << Prices as on Nov 20, 2026 - 9:54AM >>   ABB 6974.3 [ 0.23 ]ACC 1283.95 [ 1.24 ]AMBUJA CEM 400.25 [ 0.82 ]ASIAN PAINTS 2603 [ 0.35 ]AXIS BANK 1393.3 [ -1.74 ]BAJAJ AUTO 10798.55 [ -0.15 ]BANKOFBARODA 284.45 [ -0.37 ]BHARTI AIRTE 2149.35 [ 0.10 ]BHEL 428.7 [ -1.22 ]BPCL 305.25 [ -0.73 ]BRITANIAINDS 4840 [ -0.61 ]CIPLA 1421.3 [ 0.37 ]COAL INDIA 390.15 [ -0.47 ]COLGATEPALMO 1780 [ 0.28 ]DABUR INDIA 395.25 [ 1.09 ]DLF 773.1 [ 0.78 ]DRREDDYSLAB 1400.05 [ 0.15 ]GAIL 190.05 [ -0.94 ]GRASIM INDS 3113.3 [ 0.28 ]HCLTECHNOLOG 1351.2 [ 1.47 ]HDFC BANK 829.6 [ 1.11 ]HEROMOTOCORP 5582 [ 0.47 ]HIND.UNILEV 2056.65 [ -0.83 ]HINDALCO 905.1 [ -0.43 ]ICICI BANK 1614.15 [ 0.55 ]INDIANHOTELS 903.55 [ 1.32 ]INDUSINDBANK 951 [ 3.03 ]INFOSYS 1107.15 [ 1.52 ]ITC LTD 299.55 [ -0.48 ]JINDALSTLPOW 1091.4 [ 1.16 ]KOTAK BANK 507.65 [ 1.41 ]L&T 4186.75 [ -0.43 ]LUPIN 2002.15 [ 0.16 ]MAH&MAH 3513.75 [ 0.10 ]MARUTI SUZUK 13730 [ 0.96 ]MTNL 24.46 [ -1.45 ]NESTLE 1314 [ 0.66 ]NIIT 69.78 [ -0.53 ]NMDC 67.29 [ -1.35 ]NTPC 321.1 [ -1.20 ]ONGC 224.45 [ -0.02 ]PNB 152.95 [ -1.58 ]POWER GRID 262.3 [ -0.64 ]RIL 1360 [ -0.73 ]SBI 1149.1 [ -0.77 ]SESA GOA 235.4 [ -3.29 ]SHIPPINGCORP 253.3 [ 1.50 ]SUNPHRMINDS 1894.2 [ -0.46 ]TATA CHEM 663.75 [ 2.15 ]TATA GLOBAL 1157 [ 1.36 ]TATA MOTORS 263.95 [ 0.25 ]TATA STEEL 174.7 [ -3.37 ]TATAPOWERCOM 338.35 [ -0.49 ]TCS 2371.6 [ 1.07 ]TECH MAHINDR 1756.55 [ 1.95 ]ULTRATECHCEM 12792.95 [ 1.69 ]UNITED SPIRI 1465 [ 0.00 ]WIPRO 185.3 [ 0.49 ]ZEETELEFILMS 71.27 [ -0.25 ] BSE NSE
You can view full text of the latest Director's Report for the company.

BSE: 532150ISIN: INE681B01017INDUSTRY: Hospitals & Medical Services

BSE   ` 366.80   Open: 360.35   Today's Range 360.00
368.00
+6.15 (+ 1.68 %) Prev Close: 360.65 52 Week Range 293.50
542.70
Year End :2026-03 

Your Directors are pleased to present the thirty-eighth Annual Report and the audited financial statements for the financial
year ended March 31,2026.

FINANCIAL RESULTS

Particulars

2025-26

2024-25

Income from Operations

1,482.51

1,356.36

Profit before tax

246.02

216.32

Provisions for Tax

62.40

55.33

Profit for the year

183.62

160.99

Earnings per share

20.03

17.56


RESULTS OF OPERATIONS

During the year under review, the income from operations
of the Company grew by 9.3% to ' 1,482.51 Crore against
' 1,356.36 Crore in the previous year.

The profit before tax increased by 14% to ' 246.02 Crore
as compared to ' 216.32 Crore in the previous year. The
profit after tax also increased by 14% to ' 183.62 Crore as
compared to ' 160.99 Crore in the previous year.

MATERIAL CHANGES AND COMMITMENTS
AFFECTING THE COMPANY

No material changes and commitment affecting the
financial position of the Company, have occurred between
the financial year ended on March 31,2026, and the date
of the report. There has been no change in the nature of
business of the Company.

DIVIDEND

The Board of Directors has recommended a dividend of
' 4.0 per equity share (40% on face value of ' 10 per share)
on the paid-up equity share capital of the Company for
the financial year ended March 31, 2026, amounting to
' 36.67 Crore, which if approved, at the forthcoming
Annual General Meeting on September 24, 2026, will be
paid within 30 days from the date of AGM, to the Members
whose names appear in the Register of Members, as on
September 18, 2026, being the record date fixed for this
purpose. In respect of shares held in electronic form, the
dividend will be paid on the basis of beneficial ownership
furnished by the depositories viz., NSDL and CDSL for this
purpose.

The dividend recommended is in accordance with the
Company's Dividend Distribution Policy.

In view of the changes made under the Income-tax Act,
2025, dividends paid or distributed by the Company shall
be taxable in the hands of the shareholders. Your Company
shall, accordingly, make the payment of the dividend after
deduction of tax at source.

DIVIDEND DISTRIBUTION POLICY

Pursuant to Regulation 43A of the Securities and
Exchange Board of India (Listing Obligations and
Disclosure Requirements) Regulations, 2015 [SEBI Listing
Regulations], the Board of Directors of the Company had
formulated a Dividend Distribution Policy (‘the Policy'). The
Policy is available on the Company's website at https://
www.apollohospitals.com/region/delhi/pdf/Dividend-
Distribution-Policy.pdf

TRANSFER TO RESERVES

The Company does not propose to transfer any amount to
general reserve on declaration of dividend. The Board of
Directors has decided to retain the entire amount of profits
for 2025-26 in the distributable retained earnings.

SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE
COMPANIES

The Company has no subsidiaries or associate companies.
Also, it does not have any joint venture operation with any
other entity.

THE STATE OF COMPANY AFFAIRS

The Hospital remained committed to providing world
class quality healthcare and services. Focus continued on
improving operational efficiencies across functions, improving
patient services and enhancing safety for patients and staff.

During the year under review, several complex procedures

were performed by our team of clinicians, bringing respite to

many chronically ill patients and their families.

The following rare procedures were performed at the

Indraprastha Apollo Hospital:

1. First Rezum therapy for the treatment of BPH
was carried out smoothly, marking a significant
advancement in minimally invasive urological care.

2. I ndia's first leadless pacemaker (dual chamber)
implantation through a metallic prosthetic tricuspid was
performed on a 65 year old patient with a complex
cardiac history, including mechanical tricuspid valve
replacement, developed symptomatic bradyarrhythmia
requiring pacing—where conventional options were
high-risk or unfeasible. The procedure provided
effective pacing and immediate symptom relief, marking
a significant breakthrough in cardiac care.

3. A 41 year old patient had an L4-L5 disc prolapse
along with a coexisting intradural tumor at the same
level—an extremely uncommon presentation with
only six such cases reported worldwide. The patient
presented with lowback pain radiating to the right
lower limb for a duration of 2 months. A month after
the onset of symptoms, the pain started to radiate
to the left lower limb as well. Both conditions were
successfully treated in a single surgery, and the patient
was discharged without any motor neurological deficit.

4. A 45-year-old patient with ESRD and neurogenic
bladder, successfully underwent simultaneous
living donor kidney transplantation and ileal conduit
formation. Despite complex preoperative and
postoperative challenges, the patient had an uneventful
recovery with excellent graft function.

5. A 14 year old girl from Nigeria with sickle cell disease,
presented with severe left hip pain and functional
disability due to advanced avascular necrosis of the
femoral head, successfully underwent a left dual¬
mobility uncemented total hip arthroplasty with
meticulous perioperative sickle cell precautions.
Preoperative optimisation included exchange blood
transfusion to significantly reduce HbS levels before
surgery. Postoperative care was managed by a
multidisciplinary team, and she was discharged pain-
free, ambulating comfortably with support.

6. A 77 year old female patient with recurrent left
breast invasive ductal carcinoma (triple-negative)

and significant comorbidities, including hypertrophic
obstructive cardiomyopathy, underwent successful
ultrasound-guided percutaneous Cryoablation under
local anesthesia. The ice ball completely encompassed
the 1.5 cm lesion with adequate margins and no
immediate complications. The procedure and post¬
procedure course were uneventful, and the patient
was discharged the following day. Cryoablation was
performed using freeze-thaw-freeze cycles, resulting
in formation of an ice ball completely encompassing
the lesion and sufficient margin.

7. A Valve-in-Valve Transcatheter Aortic Valve
Implantation (ViV-TAVI) was performed in a patient with
a prior Bio-Bentall procedure, marking the first such
case described in medical literature. A 72-year-old
female with a degenerating bio-prosthetic aortic valve
and Chronic residual descending aortic dissection
was successfully treated using a 23 mm Navitor Vision
(Abbott) valve through a highly complex, trans-femoral
access route. The procedure was completed over
3.5 hours with excellent outcomes—the patient was
discharged in stable condition. This case is being
presented at PCR London Valves 2025, the world's
largest conference for trans-catheter heart valve
therapies.

Further, a novel HLA allele identified by Transplant
Immunology laboratory of the Hospital, has been officially
recognised and established by the WHO HLA Nomenclature
Committee and assigned the designation HLA-B*56:106,
with inclusion in the IPD-IMGT/HLA Database. This
achievement reflects the high technical expertise and
quality standards of our team and further strengthens our
institution's standing in the field of immunogenetics and
transplantation diagnostics at national and international
levels.

On a Public Interest Litigation (PIL) regarding free treatment
in the hospital, the Hon'ble Delhi High Court vide its order
dated September 22, 2009, has held that free treatment
provided by the hospital shall be inclusive of medicines &
medical consumables.

The Company has filed a Special Leave Petition (SLP) before
the Hon'ble Supreme Court of India challenging the order of
the Hon'ble Delhi High Court. The Hon'ble Supreme Court
has admitted the SLP and has passed an interim order on
November 30, 2009, pursuant to which, the Company has
been providing free treatment to the patients referred by the

The following is a summary of sexual harassment complaints received and disposed off during the year:

S. No

Particulars

Status of the No. of complaints received and disposed
off

1.

Number of complaints on Sexual harassment received

1

2.

Number of Complaints disposed off during the year

1

3.

Number of cases pending for more than ninety days

None

4.

Number of workshops or awareness programme against
sexual harassment carried out

The Company regularly conducts necessary awareness
programmes for its employees.

No. of Workshops in Delhi-203
No. of Workshops in Noida-80

5.

Nature of action taken by the employer or district officer

None

Government of NCT of Delhi and has been charging only for
medicines & medical consumables. The financial impact in
the matter can be quantified only after the final decision by
the Hon'ble Supreme Court of India.

The Directorate of Health Services, Government of NCT
of Delhi, has appointed a Nodal Officer to be permanently
stationed in the Hospital to support, guide and monitor the
treatment of patients referred by the Government.

The Company has moved an Interlocutory Application
before the Hon'ble Supreme Court seeking direction
that the conditions relating to provision of free treatment
facilities for patients belonging to indigent category to the
extent of 10% IPD and 25% OPD be made applicable to
the Company as have been made applicable in case of
other hospitals. Additionally, the Company has also made
representations before the Government of NCT of Delhi
to allow the Company to extend free treatment including
medicines and consumables up to 10% IPD and 25% OPD
as applicable to other hospitals.

During the year, a total of 48,737 patients (43,655 Out
Patients and 5,082 In Patients) were treated under the free
category.

Accreditation

Healthcare accreditation is one of the major steps towards
improving quality and patient safety. Indraprastha Apollo
Hospitals was the first hospital in the country to get Joint
Commission International (JCI) accreditation in the year
2005. It has been reaccredited for the seventh time in
December, 2023.This milestone is a testament to our
commitment to maintaining the highest standards of patient
care and safety.

CORPORATE GOVERNANCE

The Company is committed to maintain the highest
standards of corporate governance and adhere to the
corporate governance requirements set out by SEBI. The
report on corporate governance as required under the
Listing Regulations, forms an integral part of this report.
The requisite certificate from Mr. Baldev Singh Kashtwal,
Practicing Company Secretary, confirming the compliance
with the conditions of corporate governance is attached to
the report on Corporate Governance.

MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Management Discussion and Analysis Report for the year
under review, as stipulated under Listing Regulations, forms
an integral part of this report.

BUSINESS RESPONSIBILITY & SUSTAINABILITY
REPORT

As stipulated under the SEBI Listing Regulations, the
Business Responsibility and Sustainability Report forms
part of this Annual Report. The report outlines the initiatives
taken by the Company from an environmental, social and
governance perspective and is part of the Annual Report.

SEXUAL HARASSMENT POLICY

The Company has adopted a policy on prevention,
prohibition and redressal of sexual harassment at the
workplace in line with the provisions of the Sexual
Harassment of Women at Workplace (Prevention,
Prohibition and Redressal) Act, 2013 and the rules framed
thereunder. The Company has an Internal Complaints
Committee (ICC) for providing a redressal mechanism
pertaining to sexual harassment of women employees at
the work place.

VIGIL MECHANISM / WHISTLE BLOWER POLICY

The Company has established a vigil mechanism for
Directors and Employees to report their genuine concerns,
the details of which are given in the Corporate Governance
Report. The Whistle Blower Policy may be accessed on
the Company’s website on the https://cdn.apollohospitals.
com/delhi/2024/Whistle-Blower-Policy.pdf During the year,
no matter or incident has been received under the Whistle
Blower Policy of the Company.

PARTICULARS OF LOANS GIVEN, INVESTMENTS
MADE, GUARANTEES GIVEN AND SECURITIES
PROVIDED

During the year, the Company has not given any loan or
made an investment, nor given any guarantee in terms of
Section 186 of the Companies Act, 2013.

FIXED DEPOSITS

During the year, your company did not accept any deposits
or renew existing deposits from the public. The total
outstanding deposits with the Company as on March 31,
2026, is Nil.

DIRECTORS AND KEY MANAGERIAL PERSONNELBoard Composition and Independent Directors

As at the end of the day on March 31, 2026, the Board
consisted of four Non-Executive - Non-Independent
Directors, one Executive Director and eight Independent
Directors.

Independent directors are appointed, based on the
recommendation of the Nomination and Remuneration
Committee, for a term of five years and are not liable to retire
by rotation. In the opinion of the Board, the Independent
Directors fulfil the conditions specified in the Listing
Regulations and are independent of the management.

All Independent Directors have given their declarations that
they meet the criteria of independence as laid down under
Section 149(6) of the Companies Act, 2013 and Regulation
16(b) of the SEBI Listing Regulations.

In the opinion of the Board, the Independent Directors
possess the requisite expertise and experience and
are persons of high integrity and repute. They fulfill the
conditions specified in the Act and the Listing Regulations
and they are independent of the management.

Retirement by Rotation

Pursuant to Section 152 of the Companies Act 2013, Prof.
(Dr.) Mahesh Verma and Dr. Suneeta Reddy, Directors, retire
by rotation at the ensuing Annual General Meeting and
being eligible, have offered themselves for re-appointment.
Based on the outcome of the performance evaluation
process, the Board recommends their reappointment. The
notice convening the AGM, to be held on September 24,
2026, sets out the relevant details.

Change in Board Composition

Dr. Menaka Guruswamy (DIN 08742679) completed her
tenure viz. first term of five (5) consecutive years on May 22,
2025, as Independent Director on the Board of Directors
of the Company. Owing to her professional commitments
and law practice as a Senior Advocate at the Supreme
Court of India, she opted not to renew her second term as
an Independent Director on the Board of Directors of the
Company. Consequently, she ceased to be the Independent
Director of the Company.

Dr. Arun Rai (DIN 07159822) completed his tenure viz.
second term of five (5) consecutive years on May 25, 2025,
as Independent Director on the Board of Directors of the
Company. Consequently, he ceased to be the Director of
the Company.

Mr. Sudhir Jalan (DIN 00111118) has been appointed as
Independent Director of the Company, for a period of 5
consecutive years effective from August 6, 2025 to August
5, 2030.

Mr. Harsh Pati Singhania (DIN 00086742) has been
appointed as Independent Director of the Company, for a
period of 5 consecutive years effective from February 3,
2026 to February 2, 2031.

Ms. Vineeta Rai (DIN 07013113) completed her tenure viz.
first term of five (5) consecutive years on February 7, 2026
and was re-appointed as an Independent Director for the
second term of five (5) consecutive years effective from
February 8, 2026 to February 7, 2031.

Mr. Salil Singhal (DIN 00006629) completed his tenure viz.
first term of five (5) consecutive years on February 7, 2026
and was re-appointed as an Independent Director for the
second term of five (5) consecutive years effective from
February 8, 2026 to February 7, 2031.

Mr. Vinayak Chatterjee (DIN 00008933) completed his
tenure viz. second term of five (5) consecutive years on
March 31,2026, as Independent Director on the Board of
Directors of the Company. Consequently, he ceased to be
the Director of the Company.

Ms. Madhumita Ganguli (DIN 00676830) completed her
tenure viz. first term of five (5) consecutive years on June 8,
2026 and was re-appointed as an Independent Director for
the second term of five (5) consecutive years effective from
June 9, 2026 to June 08, 2031.

The Company is yet to get nomination from the Govt.
of NCT of Delhi for appointment of 3 Directors including
Chairman of the Company.

The Board places on record its appreciation for the
invaluable contribution and guidance given by Dr. Menaka
Guruswamy, Dr. Arun Rai and Mr. Vinayak Chatterjee as
Independent Directors of the Company.

Key Managerial Personnel

Pursuant to the provisions of Section 203 of the Companies
Act, 2013, the Key Managerial Personnel of the Company
are Mr. Shivakumar Pattabhiraman - Managing Director, Mr.
C. P. Tyagi - Chief Financial Officer and Mr. Priya Ranjan
- Associate Vice President - Corporate Affairs & Legal.
There has been no change in the Key Managerial Personnel
during the year.

Board Evaluation

Pursuant to the provisions of the Companies Act, 2013, and
in terms of Regulation 17(10) of the SEBI Listing Regulations,
the Board has carried out an annual performance evaluation
of its own performance, the Directors individually as well as
the working of the Committees. The manner in which the
evaluation has been carried out has been enumerated in the
Corporate Governance Report.

NOMINATION & REMUNERATION POLICY

The Board has, on the recommendation of the Nomination
and Remuneration Committee, approved a policy for
selection and appointment of Directors, Senior Management
team and their remuneration. Note on the Remuneration
Policy is mentioned in the Corporate Governance Report.

MEETINGS OF THE BOARD

The Board met five times during the financial year, the details
of which are given in the Corporate Governance Report.
The intervening gap between the Meetings was within the

period prescribed under the Companies Act, 2013, read
with the Listing Regulations.

RISK MANAGEMENT

The Board of Directors has constituted a Risk Management
Committee to identify elements of risk in different areas of
operations and to develop a policy for actions associated to
mitigating the risks. The Committee on a timely basis informed
the members of the Board about risk assessment and
minimisation procedures. In the opinion of the Committee,
there was no risk that may threaten the existence of the
Company. The details of the Risk Management Committee
are included in the Corporate Governance Report.

INTERNAL FINANCIAL CONTROLS AND THEIR
ADEQUACY

The Company has an Internal Control System,
commensurate with the size, scale and complexity of its
operations.

The Internal Audit function reports to the Audit Committee
to maintain its objectivity and independence. Details of the
internal control system and its terms of reference are set out
in the Management Discussion and Analysis Report forming
part of the Board's Report.

The Board of Directors has laid down internal financial
controls to be followed by the Company and the policies
and procedures to be adopted by the Company for ensuring
the orderly and efficient conduct of its business, including
adherence to the Company's policies, the safeguarding of
its assets, prevention and detection of frauds and errors,
the accuracy and completeness of the accounting records,
and the timely preparation of reliable financial information.
The Audit Committee evaluates the internal financial control
systems periodically.

SIGNIFICANT AND MATERIAL ORDERS PASSED BY
THE REGULATORS OR COURTS

There are no significant material orders passed by the
Regulators / Courts which would impact the going concern
status of the Company and its future operations.

DIRECTORS’ RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Companies Act 2013, the
Board of Directors, to the best of their knowledge, hereby
state and confirm:

a. that in the preparation of the annual financial
statements for the year ended March 31, 2026, the

applicable accounting standards have been followed
along with proper explanations relating to material
departures, if any;

b. that such accounting policies have been selected
and applied consistently, and judgement and
estimates have been made that are reasonable and
prudent so as to give a true and fair view of the state
of affairs of the Company as at March 31,2026, and
of the profit of the Company for the year ended on
that date;

c. that proper and sufficient care has been taken for
the maintenance of adequate accounting records in
accordance with the provisions of the Companies Act,
2013, for safeguarding the assets of the Company
and for preventing and detecting fraud and other
irregularities;

d. that the annual financial statements have been
prepared on a going concern basis;

e. that proper internal financial controls were in place and
that the financial controls were adequate and were
operating effectively;

f. that systems to ensure compliance with the provisions
of all applicable laws were in place and were adequate
and operating effectively.

SHARE CAPITAL

The paid-up Equity Share Capital as on March 31, 2026,
was ' 91.67 Crore.

During the year under review, the Company has not issued
shares with differential voting rights nor granted stock
options nor sweat equity. As of March 31,2026 the details
of shareholding in the Company held by the Directors are
set out in the Corporate Governance Report forming part of
the Board's Report.

EMPLOYEE STOCK OPTIONS

No Employee Stock Options have been granted to the
employees of the Company and thus no disclosure is
required.

CREDIT RATINGS

During the year ended March 31,2026, ICRA Limited has
reaffirmed :

a) Long-Term - Fund Based / Term Loan - credit rating of
[ICRA]AA (stable)] for Rs. 92.50 crore;

b) Long-Term - Fund Based / Cash Credit - credit rating
of [ICRA]AA(stable) for Rs. 40.00 crore; and

c) Short Term - Non-Fund Based - credit rating of [ICRA]
A1 for Rs. 30.00 crore, to the Company

CONTRACTS AND ARRANGEMENTS WITH RELATED
PARTIES

All contracts/arrangements/transactions entered by the
Company during the financial year with related parties were
in the ordinary course of business and on an arm's length
basis and approved by the Audit Committee.

During the year, the Company has not entered into any
contract / arrangement / transaction with related parties
which could be considered material in accordance with
the policy of the Company on materiality of related party
transactions. Since, there were no material transactions of
the Company with any of its related parties, disclosure of
the Related Party Transactions as required under Section
134(3)(h) of the Companies Act, 2013, in AOC-2 is not
applicable to the Company.

The details of RPTs during the financial year, including
transactions with person or entities belonging to the
promoter/ promoter group which hold(s) 10% or more
shareholding in the Company are provided in the
accompanying financial statements.

The policy on materiality of related party transactions as

approved by the Board may be accessed on the Company's

website at https://cdn.apollohospitals.com/delhi/2024/

Policy-on-Related-Party-Transaction.pdf

Your directors draw the attention of the members to Notes

to the financial statements which sets out related party

disclosures.

During the financial year, the Independent Directors of the
Company had no pecuniary relationship or transactions
with the Company other than sitting fees, commission and
reimbursement of expenses, as applicable.

PARTICULARS OF EMPLOYEES AND RELATED
DISCLOSURES

Disclosure pertaining to remuneration and other details as
required under Section 197(12) of the Act read with Rule
5(1) of the Companies (Appointment and Remuneration
of Managerial Personnel) Rules, 2014 is annexed to the
Report as Annexure -1.

Statement containing particulars of top 10 employees and
particulars of employees as required under Section 197 (12)
of the Act read with Rule 5(2) and (3) of the Companies
(Appointment and Remuneration of Managerial Personnel)
Rules, 2014 is provided as a separate Annexure forming
part of this report.

In terms of proviso to Section 136(1) of the Act, the Report
and Accounts are being sent to the Shareholders, excluding
the aforesaid Annexure. The said Statement is also open for
inspection. Any member interested in obtaining a copy of
the same may write to the Company Secretary.

INDUSTRIAL RELATIONS

The Industrial Relations continued to be cordial during the
year under review.

CORPORATE SOCIAL RESPONSIBILITY INITIATIVES

In terms of the provisions of Section 135 of the Act read
with the Companies (Corporate Social Responsibility
Policy) Rules, 2014, the Board of Directors of the Company
have constituted a Corporate Social Responsibility and
Sustainability (“CSRS”) Committee. As part of its initiatives
under CSR, the Company has focused and undertaken
projects in the areas of Rural Development, Healthcare,
Education & Skill Development and Research in Healthcare.
These projects are in accordance with Schedule VII of the
Companies Act, 2013. The Report on CSR activities for the
financial year 2025-2026 is annexed herewith marked as
Annexure - 2 to this Report.

STATUTORY AUDITORS

The Members at the Annual General Meeting held on
September 23, 2022, had approved the re-appointment
of Statutory Auditors of your Company namely, M/s S.N.
Dhawan & Co., LLP, Chartered Accountants, for the second
and final term of five consecutive years, to hold office from
the conclusion of the 34th Annual General Meeting till the
conclusion of the 39th Annual General Meeting to be held
in the year 2027.

The Report given by Statutory Auditors on the financial
statement of the Company for the financial year 2025-26
forms part of the Annual Report. The Notes on the financial
statements referred to in the Auditors' Report are self¬
explanatory and do not call for any further comments.

The Auditors' Report on the financial statements of the
Company for the financial year ended March 31, 2026,

is unmodified i.e. it does not contain any qualification,
reservation or adverse remark.

COST AUDITORS

Pursuant to Section 148 of the Companies Act, 2013, read
with the Companies (Cost Records and Audit) Amendment
Rules, 2014, the Directors on the recommendation of the
Audit Committee, appointed M/s Devarajan Swaminathan
and Co., Cost Accountants (FRN 100669), to audit the cost
accounts of the Company for the financial year 2026-27 on
a remuneration of ' 6.50 Lacs.

As required under the Companies Act, 2013, the
remuneration payable to the Cost Auditor is required to be
placed before the members in a general meeting for their
ratification. Accordingly, a resolution seeking member's
ratification for the remuneration payable to M/s Devarajan
Swaminathan and Co., Cost Accountants (FRN 100669), is
included at Item No. 5 of the Notice convening the Annual
General Meeting.

The Company has maintained cost records in accordance
with the provisions of the Companies Act, 2013, read with
the Companies (Cost Records and Audit) Amendment
Rules, 2014, in respect of healthcare services.

SECRETARIAL AUDITORS

The Members at the Annual General Meeting held on
September 24, 2025, had approved the appointment of
Secretarial Auditors of your Company namely, M/s RSM &
Co., Peer Reviewed Firm of Practicing Company Secretaries,
for a period of five consecutive years commencing from
Financial Year 2025-26 to 2029-30.

Secretarial Auditors Report

The Secretarial Audit Report for the financial year
ended March 31, 2026, is annexed herewith marked as
Annexure - 3, to this Report.

During the period under review, the Company has
complied with the provisions of the Act, Rules, Regulations,
Guidelines, Standards etc. and the same is covered under
the Secretarial Audit Report, save and except that:

(i) the Govt. of NCT of Delhi - one of the promoters of the
Company, have not dematerialized their shareholding
in the Company. Requests have been made by the
Company to the Govt. of NCT of Delhi to get their
shareholding dematerialized; and

(ii) appointment / re-appointment of Mr. Sudhir Jalan, Ms.
Vineeta Rai & Mr. Salil Singhal, who had attained the
age of 75 years and above, as Independent Directors
of the Company without obtaining prior approval of the
Shareholders.

Internal Auditors

The Board of Directors of the Company based on the
recommendations of the Audit Committee, appointed M/s
SCV & Co. LLP., as Internal Auditors to conduct Internal Audit
of the Company for a period up to September 30, 2027.

Board’s response on Auditor’s qualification, reservation
or adverse remarks or disclaimer made.

The Directors hereby confirm that there are no qualifications,
reservations or adverse remark made by the statutory
auditors of the company or in the secretarial audit report
by the practicing company secretary and secretarial
compliance report for the year ended March 31, 2026,
save and except that the Govt. of NCT of Delhi - one of the
promoters of the Company, have not dematerialised their
shareholding in the Company. Requests have been made
by the Company to the Govt. of NCT of Delhi to get their
shareholding dematerialised.

REPORTING OF FRAUDS BY AUDITORS

During the year under review, neither the statutory auditors
nor the secretarial auditors has reported to the Audit
Committee, under Section 143 (12) of the Companies
Act, 2013, any instances of fraud committed against the
Company by its officers or employees.

OTHER DISCLOSURES:

a) During the year, the Company had complied with the
applicable, Secretarial Standards relating to “Meetings
of the Board of Directors” and “General Meetings”.

b) There are no proceedings initiated/pending against
the Company under the Insolvency and Bankruptcy
Code, 2016, which materially impact the business of
the Company.

c) There were no instances where the Company required
the valuation for one time settlement or while taking
loans from the Banks or Financial Institutions.

d) During the year there has been no change in the nature
of business of the Company.

PARTICULARS REGARDING CONSERVATION OF
ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN
EXCHANGE EARNINGS AND OUTGO.

Information as required to be disclosed on conservation
of energy, technology absorption and foreign exchange
earnings and outgo stipulated under Section 134(3)
(m) of the Companies Act, 2013, read with Rule 8 of the
Companies (Accounts) Rules, 2014, is annexed herewith
marked as Annexure - 4 to this Report.

ANNUAL RETURN

In accordance with the provisions of Section 92(3) read
with section 134(3)(a) of the Companies Act, 2013, and
Rules framed thereunder, an annual return in the prescribed
format for the financial year 2025-26 is available on the
website of the Company at https://www.apollohospitals.
com/region/delhi/investor-relations/

ACKNOWLEDGEMENT

Your Directors wish to place on record their appreciation of
the contribution made by, the consultant doctors and the
employees at all levels, towards the continued growth and
prosperity of your Company.

Your Directors also wish to place on record their appreciation
of the Government of NCT of Delhi, business constituents,
bankers and other financial institutions and shareholders of
the Company for their continued support.

For and on behalf of the Board of DirectorsDr. Prathap C. Reddy

Vice Chairman
(DIN 00003654)

Place : Chennai
Date : August 06, 2026